J&J Drug Succeeds in Second Trial for Rare Blood Disease

Johnson & Johnson's experimental treatment Imaavy has now passed two major clinical trials for a rare autoimmune blood disorder, bringing hope to patients whose own immune systems attack their red blood cells.

The FDA is already fast-tracking its review under priority status.